Respiratory health company ResMed has posted strong revenue growth and double-digit earnings increase in the third quarter, helping lift margins across its global sleep and respiratory care businesses ...

ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago. These figures are ...

A decent finish to the week is expected for Aussie investors. The post 5 things to watch on the ASX 200 on Thursday appeared ...

Resmed (NYSE: RMD) shares remained unmoved after hours today on third-quarter results that came in ahead of the consensus ...

As previously communicated, in January 2025, the Company entered into a third amended and restated credit agreement with a group of existing and new lenders that increased its unsecured revolving ...

Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.9% year on year ...

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.

Academic research shows that, when a company confirms a quarterly earnings date that is later than when they have ...

Analysts are estimating that Edwards Lifesciences will report an earnings per share (EPS) of $0.59. The announcement from ...

Melbourne-based biotech Avecho has just pulled off a big move, and it could change how Aussies tackle sleepless nights.

‘The bed is important for social and physical connection. A sexual spark can be difficult to achieve in separate rooms,’Piper ...

Sleep software company ResMed, which is based in San Diego, ranked number nine on LinkedIn's list. ResMed makes medical devices for sleep disorders and employes around 3500 people in Australia.